Our Vision for SY-2101 is to Dramatically Reduce the Treatment Burden for APL Patients
SY-2101 is a novel oral form of arsenic trioxide (ATO) that we are developing for acute promyelocytic leukemia (APL), a subtype of acute myeloid leukemia (AML) that is caused by a fusion of the RARA and PML genes. We are advancing SY-2101 into a dose confirmation study, which will be followed by a planned Phase 3 study in newly diagnosed APL patients.